Related references
Note: Only part of the references are listed.A randomised trial of 4-versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
Mark Clemons et al.
EUROPEAN JOURNAL OF CANCER (2021)
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases
Bradley McGregor et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2021)
Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis
Jingcheng Chen et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2021)
Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
Veronica Mollica et al.
CANCERS (2021)
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy
Edoardo Francini et al.
JAMA NETWORK OPEN (2021)
The use of Platelet-rich Fibrin in the management of medication-related osteonecrosis of the jaw: A case series
C. Fernando de Almeida Barros Mourao et al.
JOURNAL OF STOMATOLOGY ORAL AND MAXILLOFACIAL SURGERY (2020)
New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws
Francesco Bennardo et al.
ORAL ONCOLOGY (2020)
Bone health in cancer: ESMO Clinical Practice Guidelines
R. Coleman et al.
ANNALS OF ONCOLOGY (2020)
Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review
Tae Jin Kim et al.
CANCERS (2020)
A Drug Holiday Reduces the Frequency and Severity of Medication-Related Osteonecrosis of the Jaw in a Minipig Model
Sven Otto et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial
Ie-Wen Sim et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bone metastases
Robert E. Coleman et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion
Daniele Santini et al.
ESMO OPEN (2020)
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Matthew Smith et al.
LANCET ONCOLOGY (2019)
Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.
Bertrand F. Tombal et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody
Roger von Moos et al.
CANCER TREATMENT REVIEWS (2019)
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
Noam Yarom et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges
Morten Schiodt et al.
ORAL DISEASES (2019)
Metastatic bone disease: Pathogenesis and therapeutic options Up-date on bone metastasis management
Stella D'Oronzo et al.
JOURNAL OF BONE ONCOLOGY (2019)
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials
Daniele Santini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population
Debajyoti Bhowmik et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review
Ourania Nicolatou-Galitis et al.
SUPPORTIVE CARE IN CANCER (2019)
Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review
Rebecca King et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2019)
The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review
A. F. de Groot et al.
CANCER TREATMENT REVIEWS (2018)
Management of Facial Pyoderma Gangrenosum Using Platelet-Rich Fibrin: A Technical Report
Leonzio Fortunato et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2018)
Numb chin syndrome: A reflection of malignancy or a harbinger of MRONJ? A multicenter experience
Leonzio Fortunato et al.
JOURNAL OF STOMATOLOGY ORAL AND MAXILLOFACIAL SURGERY (2018)
Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
Karim Fizazi et al.
CLINICAL GENITOURINARY CANCER (2018)
Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw
J. Chang et al.
CURRENT OSTEOPOROSIS REPORTS (2018)
Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures
Kenneth Pittman et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial
Tomomi Kamba et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases A Randomized Clinical Trial
Andrew L. Himelstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB
Si-yong Gao et al.
PLOS ONE (2017)
Interventions for managing medication-related osteonecrosis of the jaw
Natalie H. Beth-Tasdogan et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Targeting prostate cancer cells en route to dissemination
Kinam Park
JOURNAL OF CONTROLLED RELEASE (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
Impact of Bone-targeted Therapies in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302
Fred Saad et al.
EUROPEAN UROLOGY (2015)
Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)
Manfred Wirth et al.
EUROPEAN UROLOGY (2015)
Infection and Medication-related Osteonecrosis of the Jaw
H. Katsarelis et al.
JOURNAL OF DENTAL RESEARCH (2015)
Temporal Correlation Between Bisphosphonate Termination and Symptom Resolution in Osteonecrosis of the Jaw: A Pooled Case Report Analysis
Andrew M. Hinson et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2015)
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
M. R. Smith et al.
ANNALS OF ONCOLOGY (2015)
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Aliya A. Khan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 ( Alliance)
Matthew R. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Efficacy and Safety of Denosumab Versus Zoledronic Acid in Patients With Bone Metastases A Systematic Review and Meta-analysis
Lei Sun et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
F. Saad et al.
ANNALS OF ONCOLOGY (2012)
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
Matthew R. Smith et al.
LANCET (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Biochemical and molecular mechanisms of action of bisphosphonates
Michael J. Rogers et al.
BONE (2011)
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw
J. Katz et al.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2011)
Osteonecrosis of the Jaw and the Role of Macrophages
Michael Pazianas
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer
Valentina Guarneri et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings
Sebastian Hoefert et al.
CLINICAL ORAL INVESTIGATIONS (2010)
Bisphosphonate-Related Osteonecrosis of the Jaw: The Role of Actinomyces
Nimesh H. Naik et al.
CLINICAL INFECTIOUS DISEASES (2009)
Bisphosphonate-associated adverse events
Peter D. Papapetrou
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2009)
Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL
Paul J. Kostenuik et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data
Matthew R. Allen et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2009)
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid
S. Chennuru et al.
INTERNAL MEDICINE JOURNAL (2008)
Bisphosphonate nephrotoxicity
Mark A. Perazella et al.
KIDNEY INTERNATIONAL (2008)
Bisphosphonates: Mechanism of action and role in clinical practice
Mathew T. Drake et al.
MAYO CLINIC PROCEEDINGS (2008)
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy
Cherry L. Estilo et al.
ONCOLOGIST (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Imaging findings of bisphosphonate-associated osteonecrosis of the jaws
P. M. Phal et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2007)
Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy
Deepak Kademani et al.
MAYO CLINIC PROCEEDINGS (2006)
Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis
T Hansen et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2006)
Management of the adverse effects associated with intravenous bisphosphonates
T. Tanvetyanon et al.
ANNALS OF ONCOLOGY (2006)
Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease
Raoul Bergner et al.
ONKOLOGIE (2006)
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors
A Bamias et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment
RE Marx et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2005)
Lesson of the week - Severe hypocalcaemia after being given intravenous bisphosphonate
R Peter et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial)
DP Dearnaley et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency
CJ Rosen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer
EJ Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis
JR Green et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2002)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients
L Bubendorf et al.
HUMAN PATHOLOGY (2000)
Share Paper
